Abvc Biopharma vs Cervomed
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $296,000 for Abvc Biopharma (13.5 times as much). Abvc Biopharma grew faster (-41.9% against -58.9%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -2671.8%. Cervomed carries less debt relative to equity (0.0% against 6.8%).
| Latest fiscal year | Abvc BiopharmaABVC, 2025 | CervomedCRVO, 2025 |
|---|---|---|
| Revenue | $296,000 | $4.0m |
| Revenue growth | -41.9% | -58.9% |
| Net income | −$7.9m | −$27.0m |
| Operating margin | -2416.0% | -706.2% |
| Net margin | -2671.8% | -673.1% |
| Return on equity | -128.2% | -93.9% |
| Free cash flow | −$3.0m | −$23.4m |
| Cash | $681,480 | $8.2m |
| Total debt | $755,512 | $0 |
| Debt to equity | 6.8% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 15 |
| Market value | $25.6m | $21.0m |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 19 buys, 0 sales |